Table 1.
Clinical baseline characteristics of 293 PDAC patients from the CONKO-005 trial.
| Characteristics | PDAC |
|---|---|
| (n = 293) | |
| Age, years | |
| Median | 64 |
| Range | 24–82 |
| Sex | |
| male - no. (%) | 163 (56%) |
| female - no. (%) | 130 (44%) |
| Arm | |
| Gemcitabine - no. (%) | 149 (51%) |
| Gemcitabine + Erlotnib - no. (%) | 144 (49%) |
| Karnofsky | |
| 60 - no. (%) | 1 (>1%) |
| 70 - no. (%) | 10 (3%) |
| 80 - no. (%) | 75 (26%) |
| 90 - no. (%) | 112 (38%) |
| 100 - no. (%) | 95 (32%) |
| Grading | |
| G1 - no. (%) | 7 (2%) |
| G2 - no. (%) | 180 (61%) |
| G3 - no. (%) | 96 (33%) |
| unknown - no. (%) | 10 (4%) |
| T-Stage | |
| T1 - no. (%) | 9 (3%) |
| T2 - no. (%) | 30 (10%) |
| T3 - no. (%) | 251 (86%) |
| T4 - no. (%) | 3 (1%) |
| N-Stage | |
| N0 - no. (%) | 106 (36%) |
| N1 - no. (%) | 187 (64%) |
| Postoperative CA 19–9, kU/L | |
| Median (range) | 19,5 (1–5816) |
| ≤ 100 - no. (%) | 223 (76%) |
| 101–500 - no. (%) | 29 (10%) |
| > 500 - no. (%) | 12 (4%) |
| unknown - no. (%) | 29 (10%) |